J. Goldman & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

J. Goldman & Co’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-40,500	Closed	-$448K	–	569
2025 Q3	$448K	Buy	+40,500	New	+$442K	0.01%	385
2023 Q4	–	Sell	-92,800	Closed	-$721K	–	346
2023 Q3	$721K	Buy	+92,800	New	+$908K	0.03%	253
2021 Q4	–	Sell	-13,500	Closed	-$299K	–	352
2021 Q3	$299K	Buy	+13,500	New	+$214K	0.02%	305

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's AUPH Position: Q4 2025 in Review

J. Goldman & Co sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 13,500 shares — an estimated $149K sold.

J. Goldman & Co first reported a position in AUPH in Q4 2019 and held it in 8 quarters. The position peaked at $5.35M in Q2 2023. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

J. Goldman & Co reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 13,500 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $149K.
J. Goldman & Co first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 8 quarters.
J. Goldman & Co's Aurinia Pharmaceuticals position peaked at $5.35M in Q2 2023.
255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.